{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:04:50Z","timestamp":1784005490821,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esophageal adenocarcinoma (EAC) is associated with poor prognosis despite advances in multimodal treatment. High endothelial venules (HEVs) facilitate lymphocyte trafficking and are linked to anti-tumor immunity. While HEVs have shown prognostic relevance in esophageal squamous cell carcinoma and gastric cancer, their role in regional lymph nodes of EAC patients remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 199 patients with EAC who underwent Ivor-Lewis esophagectomy between 2013 and 2021. Patients received perioperative chemotherapy (FLOT), neoadjuvant chemoradiotherapy (CROSS), or primary surgery. Tumor-free regional lymph nodes were immunohistochemically stained using the MECA-79 antibody to detect HEVs. Whole-slide images were digitally analyzed to quantify HEV density. Associations with clinicopathological parameters, treatment modality, therapy response, and survival outcomes were assessed. An exploratory analysis was performed in an additional cohort of 58 patients receiving adjuvant nivolumab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HEVs were detectable in regional lymph nodes across all treatment groups. HEV density was significantly higher in patients older than 60 years compared to younger patients (p = 0.001) and was independent of treatment modality, pathological response, T-stage, and N-stage. No association was observed between HEV density and response to neoadjuvant therapy. Dichotomization into MECA-low and MECA-high groups confirmed age as the primary determinant of HEV density classification. Kaplan\u2013Meier analyses showed no significant differences in overall or progression-free survival between MECA-low and MECA-high patients in the primary cohort. In the adjuvant nivolumab cohort, MECA-high patients demonstrated a non-significant trend toward improved two-year overall survival (90% vs. 67%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HEV density in tumor-free regional lymph nodes of EAC patients is primarily age-dependent and independent of tumor stage, treatment response, and neoadjuvant therapy regimen. Although HEV density alone does not predict survival, observed trends in immunotherapy-treated patients suggest a potential modulatory role in immune responsiveness. These findings emphasize the importance of host-related immune architecture and support further investigation of lymph node\u2013based immune biomarkers in EAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1802849","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:29Z","timestamp":1784002889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and prognostic significance of high-endothelial venule density in regional lymph nodes of esophageal adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Aryan","family":"Mirzaie-Kuzehgarani","sequence":"first","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann","family":"Bedau","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Teloh-Benger","sequence":"additional","affiliation":[{"name":"Center for Integrated Oncology Cologne, University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Anton","family":"Schl\u00f6\u00dfer","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Bruns","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00262-025-04265-z","article-title":"Tumor-associated high endothelial venules are associated with enhanced lymphocyte infiltration and favorable prognosis in resected hepatocellular carcinoma","volume":"75","author":"Aoyama","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09792-8","article-title":"High endothelial venules (HEVs) in immunity, inflammation and cancer","volume":"24","author":"Blanchard","year":"2021","journal-title":"Angiogenesis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102141","article-title":"Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade","volume":"6","author":"Blanchard","year":"2025","journal-title":"CR Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082628","article-title":"High endothelial venule with concomitant high CD8+ tumor-infiltrating lymphocytes is associated with a favorable prognosis in resected gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"JCM"},{"key":"B8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40364-024-00656-z","article-title":"Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma","volume":"12","author":"Jiang","year":"2024","journal-title":"biomark Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2022.152051","article-title":"High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma","volume":"61","author":"Li","year":"2022","journal-title":"Ann Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70000","article-title":"Exploring lymph node stroma ageing: Immune implications and future directions","volume":"24","author":"Ng","year":"2025","journal-title":"Aging Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003353","article-title":"High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer","volume":"9","author":"Park","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.002","article-title":"High endothelial venules in cancer: Regulation, function, and therapeutic implication","volume":"41","author":"Vella","year":"2023","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401118","article-title":"Intratumoral high endothelial venules in solid tumors: a pooled study","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","article-title":"Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.191041","article-title":"VEGFD\/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing","volume":"10","author":"Yang","year":"2025","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1543322","article-title":"Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy","volume":"16","author":"Zhai","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616247","article-title":"Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy","author":"Zhai","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1802849\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:30Z","timestamp":1784002890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1802849\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1802849"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1802849","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1802849"}}